<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85590">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01801150</url>
  </required_header>
  <id_info>
    <org_study_id>HULP-DM-SAHS-2012</org_study_id>
    <nct_id>NCT01801150</nct_id>
  </id_info>
  <brief_title>CPAP in Diabetes Type 2 Patients With Sleep Apnea</brief_title>
  <acronym>DM-SAHS</acronym>
  <official_title>Effect Of Nasal CPAP On Glycemic Control In Patients With Poorly Controlled Type 2 Diabetes And Sleep Apnea-Hypopnea Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario La Paz</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To assess if six months of treatment with CPAP associated with conventional drug
      therapy, contribute to improved glycemic control in patients with type 2 diabetes and sleep
      apnea-hypopnea syndrome SAHS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective:

      To assess the effect of 6 months of CPAP treatment associated with conventional drug therapy
      on glycemic control in patients with type 2 diabetes and sleep apnea-hypopnea syndrome
      (SAHS)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>Six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the effect of 6 months of CPAP therapy and conventional treatment on glycemic control in patients with type 2 diabetes and sleep apnea-hypopnea syndrome (SAHS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine additional effects of CPAP on insulin resistance in patients with type 2 diabetes and SAHS.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>. Determine the medium term additional effect of CPAP on insulin resistance in patients with type 2 diabetes and SAHS.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Impact of CPAP on glycemic control</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analyze the impact of additional treatment with CPAP on serum lipids and C-reactive protein concentration in patients with type 2 diabetes and SAHS</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life after CPAP</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Establish the impact of additional treatment with CPAP on quality of life related to health of patients with type 2 diabetes and SAHS.</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory markers after CPAP</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the effect of CPAP on inflammatory cytokines, biomarkers of oxidative stress, sympathetic tone and intake regulating hormones in patients with type 2 diabetes and SAHS.</description>
  </other_outcome>
  <other_outcome>
    <measure>Endocrine control with CPAP treatment</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Relate the CPAP-induced changes in the concentration of HbA1c and HOMA index with changes produced in the basal inflammatory reaction, oxidative stress, sympathetic activity and intake regulatory hormones.
Identify the subset of patients with poorly controlled type 2 diabetes and SAHS in the six months of treatment with CPAP achieve a more pronounced reduction in HbA1c.</description>
  </other_outcome>
  <other_outcome>
    <measure>Influence of body distribution and activity on metabolic control</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To estimate the influence of the distribution of body mass and daily physical activity of patients with type 2 diabetes and SAHS on the metabolic response to treatment with CPAP.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Diabetes</condition>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>lifestyle and diabetes treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Counseil about lifestyle and current diabetes treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPAP nasal treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous positive airway pressure (CPAP) nasal during the night and current diabetes treatment. Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP nasal treatment</intervention_name>
    <description>Treatment with titred CPAP nasal during the nighttime</description>
    <arm_group_label>CPAP nasal treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects 18 to 75 years old; diagnosis of type 2 diabetes mellitus; treatment with
             diet;  oral antidiabetics or insulin stable in the last month; levels of HbA1c&gt; 7.5%
             (if not supported clinic two controls to confirm with a difference not exceeding
             0.5%); overweight or obese (BMI ≥ 25 kg/m2)

        Exclusion Criteria:

          -  professional drivers, risk profession or respiratory failure; excessive daytime
             sleepiness is very high (Epworth scale&gt; 18); morbid obesity (BMI&gt; 40 kg/m2); CPAP
             treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Garcia-Rio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz, IdiPAZ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabet Martínez-Cerón, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz, IdiPAZ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Alonso-Fernández, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Son Espasses</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabet Martínez</last_name>
    <phone>917277253</phone>
    <email>martienzcerone@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario La Paz- IdiPaz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco García Rio</last_name>
      <phone>917277253</phone>
      <email>fgr01@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elisabet Martínez- Cerón</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 26, 2013</lastchanged_date>
  <firstreceived_date>November 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario La Paz</investigator_affiliation>
    <investigator_full_name>Francisco Garcia-Rio</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Apnea- hypopnea Syndrome</keyword>
  <keyword>Glycemic control</keyword>
  <keyword>Prevalence</keyword>
  <keyword>SAHS</keyword>
  <keyword>life quality</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
